StockNews.com Begins Coverage on T2 Biosystems (NASDAQ:TTOO)

StockNews.com assumed coverage on shares of T2 Biosystems (NASDAQ:TTOOFree Report) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

T2 Biosystems Price Performance

Shares of NASDAQ:TTOO opened at $0.32 on Monday. The stock’s 50-day simple moving average is $0.47 and its two-hundred day simple moving average is $2.21. T2 Biosystems has a 52-week low of $0.31 and a 52-week high of $6.95.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC acquired a new stake in shares of T2 Biosystems, Inc. (NASDAQ:TTOOFree Report) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned approximately 9.49% of T2 Biosystems as of its most recent SEC filing. Hedge funds and other institutional investors own 23.18% of the company’s stock.

T2 Biosystems Company Profile

(Get Free Report)

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.

Further Reading

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.